Category Archives: Merger & Acquisition

Investor Alert: Qiagen grabs Spanish biotech STAT-Dx in quest for new and better diagnostic tests. My personal take.

The News: Molecular diagnostics company Qiagen NV (Hilden DEU) has agreed to acquire biotech STAT-Dx SL (Barcelona) for up to €153 million–over 3 times the total funding the Spanish company has raised… Read more »

Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

The News: Denmark’s Novo Nordisk A/S (Copenhagen), the world’s biggest insulin maker, went public Monday (January 8, 2018) with a €2.6-billion ($3.1 billion) bid for Belgian biotech group Ablynx NV… Read more »

London-based biotech TopiVert, although invisible, intends to shake up Allergan, Shire in the huge dry-eye space.

The News: TopiVert Pharma Ltd., a clinical-stage biotechnology company developing narrow spectrum kinase inhibitors (NSKIs) for chronic inflammatory gastrointestinal (GI) and ocular diseases, has announced results from a Phase 1/2a… Read more »

Germany’s Merck puts consumer drugs business up for sale; does this signal a last-ditch shot at M&A or just shoring up existing pipeline?

The News: Merck KGaA (Darmstadt DEU) put its consumer-health unit on the block Tuesday (September 5, 2017) in a move that will focus its healthcare activities on the riskier business… Read more »

Tesaro says it’s for sale, but who can afford it

The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

Biogen spinoff Bioverativ buys Bristol-Myers’ iPierian spinout True North for $825 million; deal shows how to get several bites at the same assets

The News: Bioverativ Inc. (Waltham MA) announced that it entered into a definitive agreement to acquire True North Therapeutics Inc. (South San Francisco) for up to $825 million, including an… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Walgreens cuts offer for Rite Aid, casting doubt on merger; analysts say deal still alive

The News: Walgreens Boots Alliance (Deerfield IL) on Monday (January 30, 2017) entered into a new agreement with Rite Aid (Camp Hill PA) to buy the drugstore chain for at least $2 less per share… Read more »

J&J finally captures Actelion for $30 billion; deal looks good for both unless “what ifs” bite pharma giant’s shareholders

The News: It took months but Swiss biotech Actelion Ltd. (Allschwil) said on Thursday (January 26, 2017) it had agreed to be purchased by Johnson & Johnson (New Brunswick NJ) in a… Read more »